Seth Yakatan brings more than 20 years of experience as a corporate finance professional, actively supporting small cap and major companies in achieving corporate, financing and asset monetization objectives through the successful structuring and management of strategic transactions and investments totaling more than several billion dollars in value. Over the past twelve years as a co-founder of Katan Associates (KAI), Seth has successfully structured and managed strategic alliances and deals, based on his insight and expertise in the US and Global Life Science sector, including numerous buy- and sell-side M&A transactions. In this Wall Street View, our host spoke with Seth Yakatan of Katan Associates at the LD Micro "Main Event" 2014 in Bel Air, CA.
Mr. Yakatan begins with an overview of what’s going on in the biotech market for microcaps, “It’s getting harder, you know, there’s been a party going on for the last 18 months and a lot of people have made money, a lot of people have taken money and a lot of stocks have gone out and I just don’t know how much longer that remains. Some of the underwriters that you and I talk to seem to be pulling back on their desire to do these deals. There’s still a lot of money out there and there’s still, you know a lot of investor interest. So I think ‘strike while the iron is hot’ is probably what I would tell people on the microcap side.”
He goes into what diseases biotech investors are currently focusing on, “I’m seeing a lot of interest in orphan diseases right now, I mean look I think cancer from a research dollar perspective, from a company dollar perspective is probably going to be number one always, but you know things that I think could potentially come back into favor are things like Alzheimer’s Disease. You know, you’ve seen a huge uptick in cancer immunotherapy in the last nine months, three years ago I couldn’t get somebody to take a meeting for a cancer immunotherapy company. You know, if I had to pick I like orphan diseases a lot, but I also have seen some very, very interesting strategies recently where people are taking a strategy of effectively trying to bring a lower-priced biologic to market to compete against something that’s approved.”
He discusses what countries in the international community are bringing interesting contributions to the biotech space, “I’m seeing a lot of interesting stuff come out of South Korea, for those that are involved in the biotech space or the life sciences space, South Korea is a known. There’s very good sciences, there’s a large healthcare infrastructure there but I’m seeing a lot of crossover companies from there recently where I haven’t seen them. You know, placed like Australia and Israel and places like that tend to be a little bit more well discovered, but I’m seeing some really interesting stuff come out of South Korea these days.” For more information, check out their website: www.KatanAssociates.com
© 2017 Stock News Now
Supported by Superior Web Solutions